文献速递生殖医学

供精辅助生殖技术:全国趋势与围产结局

Assisted reproductive technology with donor sperm: national trends and perinatal outcomes.
PubMed 文献 · Am J Obstet Gynecol · 2017-12-29

该回顾性队列研究利用美国国家辅助生殖技术监测系统数据,分析1996至2014年供精辅助生殖技术的使用趋势及2010至2014年新鲜自体卵母细胞周期的治疗与围产结局。供精周期占比从1996年3.8%升至2014年6.2%。校正母亲年龄后供精与活产可能性增加相关(aRR 1.06,95%CI 1.01-1.10),围产结局临床相似。

要点

  • 2014年供精辅助生殖周期占全部周期的6.2%,较1996年的3.8%上升。
  • 校正母亲年龄后,供精周期活产可能性增加(aRR 1.06,95%CI 1.01-1.10)。
  • 每单胎活产中,供精与低出生体重略低相关(aRR 0.91,95%CI 0.83-0.99)。

核心结论

  • 美国供精辅助生殖技术使用增加,2014年约占全部辅助生殖周期的6%。
  • 供精与非供精周期的辅助生殖治疗及围产结局在临床上相似。

研究设计与样本

  • 回顾性队列研究,使用美国疾病控制与预防中心国家辅助生殖技术监测系统数据,覆盖约98%的辅助生殖周期(定义排除宫腔内人工授精)。
  • 趋势分析纳入1996至2014年所有供精与自体卵母细胞的冻存和新鲜辅助生殖周期(n=1,710,034)。
  • 结局分析仅纳入2010至2014年新鲜自体卵母细胞周期(n=437,569),排除取卵前取消的周期。

主要发现

  • 1996至2014年所有周期中,74,892个(4.4%)使用供精。
  • 2014年供精辅助生殖周期为7351个,1996年为1763个(占全部周期的6.2% vs 3.8%)。
  • 2010至2014年所有自体卵母细胞周期中,供精周期活产率(27.9%)低于非供精周期(32.5%);校正母亲年龄后,供精与活产可能性增加相关(aRR 1.06,95%CI 1.01-1.10)。
  • 每移植周期,供精与非供精活产率无显著差异(31.9% vs 36.8%;aRR 1.04,95%CI 0.998-1.09)。
  • 每单胎活产,早产率无显著差异(11.5% vs 11.8%;aRR 0.98,95%CI 0.90-1.06);低出生体重在供精周期略低(8.8% vs 9.4%;aRR 0.91,95%CI 0.83-0.99)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Information regarding the use of donor sperm in assisted reproductive technology, as well as subsequent treatment and perinatal outcomes, remains limited. Outcome data would aid patient counseling and clinical decision making. OBJECTIVES: The objectives of the study were to report national trends in donor sperm utilization and live birth rates of donor sperm-assisted reproductive technology cycles in the United States and to compare assisted reproductive technology treatment and perinatal outcomes between cycles using donor and nondonor sperm. We hypothesize these outcomes to be comparable between donor and nondonor sperm cycles. STUDY DESIGN: This was a retrospective cohort study using data from all US fertility centers reporting to the Centers for Disease Control and Prevention's National Assisted Reproductive Technology Surveillance System, accounting for ∼98% of assisted reproductive technology cycles (definition excludes intrauterine insemination). The number and percentage of assisted reproductive technology cycles using donor sperm and rates of pregnancy, live birth, preterm birth (<37 weeks), and low birthweight (<2500 g) were the primary outcomes measured. Treatments assessed include use of donor vs nondonor sperm. The trends analysis included all banking and fresh assisted reproductive technology cycles using donor and autologous oocytes performed between 1996 and 2014 (n = 1,710,034). The outcomes analysis was restricted to include only fresh autologous cycles performed between 2010 and 2014 (n = 437,569) to focus on cycles with a potential outcome and cycles reflective of current practice, thereby improving the clinical relevance. Cycles canceled prior to retrieval were excluded. Statistical analysis included linear regression to explore polynomial trends and log-binomial regression to estimate relative risk for outcomes among cycles using donor and nondonor sperm. RESULTS: Of all banking and fresh donor and autologous oocyte assisted reproductive technology cycles performed between 1996 and 2014, 74,892 (4.4%) used donor sperm. In 2014, 7351 assisted reproductive technology cycles using donor sperm were performed, as compared with 1763 in 1996 (6.2% vs 3.8% of all cycles). Among all autologous oocyte cycles performed between 2010 and 2014, the live birth rate was lower for donor sperm (27.9%) than nondonor sperm cycles (32.5%); however, after adjustment for maternal age, donor sperm use was associated with an increased likelihood of live birth (adjusted relative risk, 1.06, 95% confidence interval, 1.01-1.10). Per transfer, there was no significant difference in live birth rates for donor vs nondonor sperm (31.9% vs 36.8%; adjusted relative risk, 1.04, 95% confidence interval, 0.998-1.09). Per singleton live birth, there was no significant difference in preterm birth (11.5% vs 11.8%; adjusted relative risk, 0.98, 95% confidence interval, 0.90-1.06); however, low birthweight delivery was slightly lower in donor sperm cycles (8.8% vs 9.4%; adjusted relative risk, 0.91, 95% confidence interval, 0.83-0.99). CONCLUSION: Donor sperm use in assisted reproductive technology has increased in the United States, accounting for approximately 6% of all assisted reproductive technology cycles in 2014. Assisted reproductive technology treatment and perinatal outcomes were clinically similar in donor and nondonor sperm cycles.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Gerkowicz SA, Crawford SB, Hipp HS, et al. Assisted reproductive technology with donor sperm: national trends and perinatal outcomes. Am J Obstet Gynecol. 2017. PMID: 29291411. doi:10.1016/j.ajog.2017.12.224

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。